AHCCCS does not cover Wegovy or Zepbound for weight loss

AHCCCS, Arizona's Medicaid program, lists medications used for weight loss treatment among its pharmacy benefit exclusions, so it does not cover Wegovy, Zepbound, Wegovy tablets, Foundayo or Saxenda for weight loss. Its fee-for-service criteria cover Wegovy only to lower the risk of major cardiovascular events or for MASH, with prior authorization.125

AHCCCS's fee-for-service prior authorization guidelines (Optum Rx) deny any GLP-1 request for weight loss as a plan exclusion. Wegovy can be approved for two other uses, and the diabetes GLP-1s need a type 2 diabetes diagnosis.234567

• Weight loss: Wegovy injection and Wegovy tablets for weight loss are a benefit exclusion; a GLP-1 request to treat weight loss or conditions caused by obesity, such as Zepbound for obstructive sleep apnea, is denied as a plan exclusion.
• Wegovy, cardiovascular path (injection or tablets): age 45 or older, a BMI of 30 or more, established cardiovascular disease such as a prior heart attack, use with a reduced-calorie diet and more physical activity, after a heart attack current use of a cholesterol drug, beta blocker, ACE inhibitor or ARB and antiplatelet (or intolerance to them), no diabetes and an A1C under 6.5%, no class IV heart failure and no end-stage kidney disease. Approval lasts 6 months.
• Wegovy, MASH path (injection): age 18 or older, MASH without cirrhosis, F2 or F3 fibrosis confirmed by a listed noninvasive test or a liver biopsy in the past 12 months, use with lifestyle changes, prescribed by or with a gastroenterologist, hepatologist or endocrinologist, no other GLP-1, and no use with Rezdiffra.
• Diabetes GLP-1s (Mounjaro, Trulicity, Victoza or liraglutide): type 2 diabetes with a baseline A1C of 6.5% or more shown in medical records, a 90-day metformin trial of at least 1,500 mg a day (or a reason metformin cannot be used), age 10 or older, not for weight loss, and no other GLP-1 at the same time. Approval lasts 12 months.
• Non-preferred Ozempic injection: the same diabetes criteria plus 90-day trials of Trulicity, Victoza or liraglutide, and Mounjaro, and age 18 or older.

Coverage for other uses the FDA has approved:

• Wegovy (injection), reduction of the risk of major adverse cardiovascular events in adults 45 or older with a BMI of 30 or more and established cardiovascular disease, without diabetes: Covered with prior authorization3
• Wegovy (injection), noncirrhotic MASH with F2 or F3 liver fibrosis (injection): Covered with prior authorization4
• Zepbound, obstructive sleep apnea, treated as a condition caused by obesity and denied as a plan exclusion: Not covered5

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no AHCCCS announcement that Arizona has joined.11

Arizona's state employee medical plans, run by the Arizona Department of Administration, use MedImpact for prescription drugs, and the formulary is posted on the Benefit Options site. We found no public plan document that states its GLP-1 weight-loss policy.12

Pharmacy benefit: MedImpact (prescription drugs).

Marketplace (ACA) plans: Arizona's essential health benefits benchmark plan, the State of Arizona EPO employee health plan, excludes all medications given for weight loss or obesity.15

Since Oct. 1, 2026, the preferred diabetes GLP-1s are Mounjaro, Trulicity and Victoza (brand or generic liraglutide), each with prior authorization; Ozempic injection, Ozempic tablets and Rybelsus are non-preferred. Approval needs type 2 diabetes with an A1C of 6.5% or more and a metformin trial, and a request for weight loss is denied.678910

In 2025, AHCCCS paid for 90,826 GLP-1 prescriptions, $96.9 million before rebates: 12 per 1,000 residents, against 32 across the states and DC, 42nd of 51.64 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 47 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.3940303126341929

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.2627281934353637383332
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.212319

In 2024, Medicare Part D drug plans paid for 366,689 GLP-1 claims from prescribers in Arizona, $490.1 million in total drug cost.65

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.69 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Arizona on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7071 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

The FDA’s register lists 2 outsourcing facilities (503B) in Arizona, as of November 6, 2026; 0 show no inspection date and 2 were issued a Form 483.66

FDA warning letters naming a GLP-1, sent to a company in Arizona:67